Have a feature idea you'd love to see implemented?
Let us know!
URGN UroGen Pharma Ltd
Price (delayed)
$11.55
Market cap
$487.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.09
Enterprise value
$483.34M
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel,
Highlights
The quick ratio has grown by 33% YoY and by 10% from the previous quarter
The company's EPS rose by 27% YoY and by 4% QoQ
UroGen Pharma's equity has soared by 161% YoY but it has decreased by 16% from the previous quarter
URGN's debt is up by 24% since the previous quarter and by 22% year-on-year
The net income is down by 10% YoY
Key stats
What are the main financial stats of URGN
Market
Valuations
Earnings
Shares outstanding
42.2M
Market cap
$487.4M
Enterprise value
$483.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
19.06
Price to sales (P/S)
5.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.41
Revenue
$89.36M
EBIT
-$99.13M
EBITDA
-$97.82M
Free cash flow
-$96.38M
Per share
Balance sheet
Liquidity
EPS
-$3.09
Free cash flow per share
-$2.24
Book value per share
$0.61
Revenue per share
$2.07
TBVPS
$7.01
Total assets
$301.94M
Total liabilities
$276.43M
Debt
$121.92M
Equity
$25.52M
Working capital
$262.31M
Debt to equity
4.78
Current ratio
9
Quick ratio
8.34
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-109.5%
Gross margin
90.3%
Net margin
-129.1%
Operating margin
-93.7%
Return on assets
-47.9%
Return on equity
N/A
Return on invested capital
-58.2%
Return on capital employed
-36.8%
Return on sales
-110.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
URGN stock price
How has the UroGen Pharma stock price performed over time
Intraday
0.87%
1 week
-2.61%
1 month
-7.75%
1 year
-8.84%
YTD
-23%
QTD
-9.06%
Financial performance
How have UroGen Pharma's revenue and profit performed over time
Revenue
$89.36M
Gross profit
$80.67M
Operating income
-$83.73M
Net income
-$115.38M
Gross margin
90.3%
Net margin
-129.1%
The gross profit rose by 19% year-on-year and by 6% since the previous quarter
The company's operating income fell by 18% YoY and by 5% QoQ
The revenue has grown by 16% YoY and by 5% from the previous quarter
The net income is down by 10% YoY
Growth
What is UroGen Pharma's growth rate over time
Valuation
What is UroGen Pharma stock price valuation
P/E
N/A
P/B
19.06
P/S
5.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.41
The company's EPS rose by 27% YoY and by 4% QoQ
UroGen Pharma's equity has soared by 161% YoY but it has decreased by 16% from the previous quarter
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 3039.8 and 9% lower than the last 4 quarters average of 6.1
The revenue has grown by 16% YoY and by 5% from the previous quarter
Efficiency
How efficient is UroGen Pharma business performance
The ROA has increased by 39% YoY and by 10% from the previous quarter
URGN's return on invested capital is up by 15% since the previous quarter and by 3.2% year-on-year
The company's return on sales rose by 4.8% YoY and by 2.1% QoQ
Dividends
What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for URGN.
Financial health
How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 9% higher than its total liabilities
UroGen Pharma's total assets has surged by 56% YoY and by 7% QoQ
The quick ratio has grown by 33% YoY and by 10% from the previous quarter
UroGen Pharma's equity has soared by 161% YoY but it has decreased by 16% from the previous quarter
The debt to equity is up by 48% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.